Filing Flows › Vanda Pharmaceuticals (VNDA) › Q3 2026
Vanda Pharmaceuticals (VNDA) Q3 2026 earnings results (third quarter 2026)
10-Q filed Oct 29, 2026
Vanda Pharmaceuticals (VNDA) reported revenue of $69.8M for the third quarter 2026 (Q3 2026), +24% from a year earlier and +38% from the quarter before. Operating margin was -33.7%, net loss $22.6M (32.3% of revenue).
Vanda Pharmaceuticals, Q3 2026: revenue $69.8M (+24% year over year), operating margin -33.7%, net loss $22.6M, operating cash flow −$28.4M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $69.8M | +38% | +24% |
| Operating profit | −$23.5M | — | — |
| Net earnings | −$22.6M | — | — |
| Operating cash flow | −$28.4M | — | — |
What changed
Revenue was $69.8M in Q3 2026, up 24% year over year and up 38% from the previous quarter. Fanapt® was the largest line at 56% of revenue. Fanapt® added $7.5M year over year (up 24%), 55% of the total change.
Operating costs exceeded revenue by $23.5M, an operating margin of -33.7%. Total costs grew 7% against revenue growth of 24%. The fastest-growing cost line was Cost of revenue (+41%). The quarter ended with a net loss of $22.6M, narrower than the previous quarter's $62.5M loss.
Operating cash flow was −$28.4M. Non-cash charges added back $2.2M of depreciation and amortization and $2.3M of share-based compensation. Working capital and other items used $10.4M. Capital expenditures of $311K exceeded it, leaving free cash flow of −$28.7M.
Questions
What was Vanda Pharmaceuticals' revenue in the third quarter 2026?
Vanda Pharmaceuticals (VNDA) reported revenue of $69.8M for the third quarter 2026 (Q3 2026), +24% from a year earlier and +38% from the quarter before.
Was Vanda Pharmaceuticals profitable in the third quarter 2026?
Operating loss was $23.5M (-33.7% of revenue) and net loss $22.6M.